奥沙利铂诱导的免疫性血小板减少症：一例病例报告并文献复习。
Oxaliplatin-induced Immune Thrombocytopenia: A Case Report and Literature Review.
机构信息
Department of Internal Medicine, Temple University Hospital, Philadelphia, PA.
Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA.
出版信息
Clin Colorectal Cancer. 2021 Mar;20(1):e1-e4. doi: 10.1016/j.clcc.2020.07.007. Epub 2020 Jul 30.
Abstract
Oxaliplatin-induced immune thrombocytopenia is a rare manifestation of oxaliplatin hypersensitivity, presenting as an acute onset of severe thrombocytopenia after oxaliplatin administration. No standard therapeutic approach outside of permanent discontinuation of oxaliplatin exists. Here, we present a case of oxaliplatin-induced immune thrombocytopenia occurring after oxaliplatin retreatment for metastatic colon cancer. Possible mechanisms of disease and approach to treatment are discussed.
摘要
奥沙利铂引起的免疫性血小板减少症是奥沙利铂过敏的一种罕见表现，在奥沙利铂给药后急性发作严重血小板减少症。除了永久停用奥沙利铂外，目前尚无标准的治疗方法。在这里，我们报告了一例转移性结肠癌奥沙利铂再治疗后发生的奥沙利铂诱导的免疫性血小板减少症病例。讨论了疾病的可能发病机制和治疗方法。
相似文献
1
Oxaliplatin-induced Immune Thrombocytopenia: A Case Report and Literature Review.奥沙利铂诱导的免疫性血小板减少症：一例病例报告并文献复习。
Clin Colorectal Cancer. 2021 Mar;20(1):e1-e4. doi: 10.1016/j.clcc.2020.07.007. Epub 2020 Jul 30.
2
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.高危 II 期结直肠癌辅助化疗 3 个月与 6 个月的持续时间和效果评估：TOSCA 随机临床试验的亚组分析。
JAMA Oncol. 2020 Apr 1;6(4):547-551. doi: 10.1001/jamaoncol.2019.6486.
3
Oxaliplatin-induced immune mediated thrombocytopenia.奥沙利铂诱导的免疫介导性血小板减少症。
Cancer Chemother Pharmacol. 2008 Oct;62(5):925-7. doi: 10.1007/s00280-007-0675-5. Epub 2008 Jan 19.
4
Middle-Aged Man With Acute Thrombocytopenia Subsequent to Fluorouracil and Oxaliplatin Chemotherapy for Colorectal Cancer.一名中年男性在接受氟尿嘧啶和奥沙利铂化疗治疗结直肠癌后出现急性血小板减少症
Oncology (Williston Park). 2016 Nov 15;30(11):992-4, 1000-1.
5
The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia.贝伐珠单抗联合奥沙利铂化疗对肝窦内皮损伤和血小板减少的影响。
J Natl Cancer Inst. 2018 Aug 1;110(8):888-894. doi: 10.1093/jnci/djx288.
6
[Interstitial lung disease associated with combination chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin].[与奥沙利铂、5-氟尿嘧啶和亚叶酸联合化疗相关的间质性肺疾病]
Korean J Gastroenterol. 2010 May;55(5):340-3. doi: 10.4166/kjg.2010.55.5.340.
7
Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.III期和高危II期结直肠癌患者序贯辅助化疗的可行性：采用3个月的奥沙利铂方案，随后3个月的卡培他滨：JSWOG-C2研究
Drug Des Devel Ther. 2016 Nov 23;10:3827-3835. doi: 10.2147/DDDT.S112322. eCollection 2016.
8
Leucovorin-induced Hypersensitivity Reaction in a Patient with Metastatic Colorectal Cancer Treated with Cetuximab Plus FOLFOX Chemotherapy: A Case Report.亚叶酸钙引起的过敏反应：西妥昔单抗联合 FOLFOX 化疗治疗转移性结直肠癌 1 例报告
Korean J Gastroenterol. 2023 Dec 25;82(6):288-294. doi: 10.4166/kjg.2023.114.
9
Acute immune-mediated thrombocytopenia due to oxaliplatin administration: a case report.奥沙利铂给药所致急性免疫介导性血小板减少症：一例报告
Tumori. 2010 Jan-Feb;96(1):154-6. doi: 10.1177/030089161009600125.
10
Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.贝伐单抗联合FOLFIRI或FOLFOX作为氟尿嘧啶、伊立替康和奥沙利铂治疗失败后转移性结直肠癌患者的三线或后续治疗：一项回顾性分析
Med Oncol. 2009;26(1):32-7. doi: 10.1007/s12032-008-9077-8. Epub 2008 May 22.
引用本文的文献
1
The Influence of Pelvic Bone Dose-volume Parameters on Bone Marrow Suppression During Radiation Therapy in Patients With Stage I to III Rectal Cancer Based on Real-world Data.基于真实世界数据的I至III期直肠癌患者放疗期间骨盆骨剂量体积参数对骨髓抑制的影响
Adv Radiat Oncol. 2024 Oct 24;10(1):101662. doi: 10.1016/j.adro.2024.101662. eCollection 2025 Jan.
2
Oxaliplatin Antibody-Related Thrombocytopenia: A Case Report.奥沙利铂抗体相关血小板减少症：一例报告
Cureus. 2024 Sep 4;16(9):e68621. doi: 10.7759/cureus.68621. eCollection 2024 Sep.
3
Risk Factors of Chemotherapy-Induced Thrombocytopenia After Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancies.胃肠道恶性肿瘤奥沙利铂化疗后化疗相关性血小板减少症的危险因素。
J Gastrointest Cancer. 2024 Sep;55(3):1144-1153. doi: 10.1007/s12029-024-01059-x. Epub 2024 May 7.
4
Chemotherapy-induced microbiota exacerbates the toxicity of chemotherapy through the suppression of interleukin-10 from macrophages.化疗诱导的微生物组通过抑制巨噬细胞中的白细胞介素-10 来加剧化疗的毒性。
Gut Microbes. 2024 Jan-Dec;16(1):2319511. doi: 10.1080/19490976.2024.2319511. Epub 2024 Feb 24.
5
Predictive Model of Oxaliplatin-induced Liver Injury Based on Artificial Neural Network and Logistic Regression.基于人工神经网络和逻辑回归的奥沙利铂所致肝损伤预测模型
J Clin Transl Hepatol. 2023 Dec 28;11(7):1455-1464. doi: 10.14218/JCTH.2023.00399. Epub 2023 Dec 4.
6
A severe oxaliplatin immune-induced syndrome after oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC).基于奥沙利铂的加压腹腔内气溶胶化疗（PIPAC）后出现严重的奥沙利铂免疫诱导综合征。
Pleura Peritoneum. 2022 Jan 31;7(1):35-38. doi: 10.1515/pp-2021-0138. eCollection 2022 Mar 1.
7
Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer.一名结直肠癌患者中与帕尼单抗相关的药物性免疫性血小板减少症
Case Rep Oncol. 2021 Feb 25;14(1):85-89. doi: 10.1159/000512821. eCollection 2021 Jan-Apr.
本文引用的文献
1
Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies.接受奥沙利铂治疗的患者存在因多种药物依赖性抗体导致血小板减少的风险。
Blood. 2018 Mar 29;131(13):1486-1489. doi: 10.1182/blood-2017-10-812461. Epub 2018 Feb 12.
2
Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study.奥沙利铂免疫诱导综合征与累积给药及再次激发有关：单机构系列研究和系统评价研究
Clin Colorectal Cancer. 2016 Sep;15(3):213-21. doi: 10.1016/j.clcc.2016.02.001. Epub 2016 Feb 19.
3
Acute immune hematological complication of oxaliplatin. A series of 3 cases.奥沙利铂的急性免疫血液学并发症。3例病例系列。
Tumori. 2014 Jan-Feb;100(1):e17-9. doi: 10.1700/1430.15831.
4
Oxaliplatin-induced immune-mediated cytopenias: a case report and literature review.奥沙利铂诱导的免疫介导血细胞减少症：一例报告及文献综述。
J Oncol Pharm Pract. 2015 Apr;21(2):148-56. doi: 10.1177/1078155213520262. Epub 2014 Feb 5.
5
A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia.药物诱导免疫性血小板减少症的实验室检测的系统评价。
J Thromb Haemost. 2013 Jan;11(1):169-76. doi: 10.1111/jth.12052.
6
Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer.奥沙利铂急性神经毒性的临床特征及相关因素：170 例结直肠癌患者的前瞻性研究。
Cancer. 2013 Jan 15;119(2):438-44. doi: 10.1002/cncr.27732. Epub 2012 Jul 11.
7
Platinum compounds: a hope for future cancer chemotherapy.铂类化合物：未来癌症化疗的希望。
Anticancer Agents Med Chem. 2013 Feb;13(2):296-306. doi: 10.2174/1871520611313020016.
8
Oxaliplatin-related thrombocytopenia.奥沙利铂相关性血小板减少症。
Ann Oncol. 2012 Aug;23(8):1937-1942. doi: 10.1093/annonc/mds074. Epub 2012 Apr 25.
9
A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin.长期使用奥沙利铂后并发自身免疫性溶血性贫血和血小板减少症致急性肾损伤 1 例
Clin Exp Nephrol. 2012 Jun;16(3):490-4. doi: 10.1007/s10157-012-0620-8. Epub 2012 Mar 27.
10
Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma.利妥昔单抗联合化疗作为一线治疗方案可提高老年套细胞淋巴瘤患者的总生存期。
Blood. 2011 Nov 3;118(18):4808-16. doi: 10.1182/blood-2011-04-348367. Epub 2011 Aug 26.
Zotero 插件